Prestige Consumer Healthcare (PBH) Financials

$84.88 +0.47 (+0.55%)

Closing price 03:59 PM Eastern

Extended Trading

$85.04 +0.16 (+0.19%)

As of 06:35 PM Eastern

Annual Income Statements for Prestige Consumer Healthcare

This table shows Prestige Consumer Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/31/2025	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016	3/31/2015
Net Income / (Loss) Attributable to Common Shareholders	215	209	-82	205	165	142	-36	2,422	69	100	78
Consolidated Net Income / (Loss)	215	209	-82	205	165	142	-36	340	69	100	78
Net Income / (Loss) Continuing Operations	215	209	-82	205	165	142	-36	2,422	69	100	78
Total Pre-Tax Income	284	276	-94	262	204	191	-38	107	111	157	127
Total Operating Income	337	342	-22	330	297	291	68	215	206	260	208
Total Gross Profit	634	624	625	621	547	552	556	577	500	467	406
Total Revenue	1,138	1,125	1,128	1,087	943	963	976	3,124	882	806	715
Operating Revenue	1,138	1,125	1,128	1,087	943	963	976	1,041	882	803	710
Total Cost of Revenue	503	501	502	466	396	411	420	465	382	339	308
Operating Cost of Revenue	503	501	502	466	396	411	420	465	382	339	308
Total Operating Expenses	298	282	648	291	250	261	488	361	295	207	199
Selling, General & Admin Expense	108	106	107	107	83	89	90	85	89	72	81
Marketing Expense	156	153	145	157	141	147	143	147	128	111	100
Depreciation Expense	21	23	25	25	24	25	27	28	25	24	18
Impairment Charge	12	0.00	370	1.06	2.43	-	229	100	0.00	0.00	-
Total Other Income / (Expense), net	-53	-66	-72	-67	-93	-100	-106	-108	-95	-103	-80
Interest Expense	48	67	69	66	95	98	105	109	95	103	81
Other Income / (Expense), net	-4.95	0.76	-2.34	-1.05	1.37	-1.63	-0.48	0.39	-0.03	-	1.13
Income Tax Expense	70	67	-12	57	39	49	-2.26	-232	41	57	49
Basic Earnings per Share	$4.32	$4.21	($1.65)	$4.09	$3.28	$2.81	($0.69)	$6.40	$1.31	$1.89	$1.50
Weighted Average Basic Shares Outstanding	49.70M	49.76M	49.89M	50.26M	50.21M	50.72M	52.07M	53.10M	52.98M	52.75M	52.17M
Diluted Earnings per Share	$4.29	$4.17	($1.65)	$4.04	$3.25	$2.78	($0.69)	$6.34	$1.30	$1.88	$1.49
Weighted Average Diluted Shares Outstanding	50.08M	50.18M	49.89M	50.84M	50.61M	51.14M	52.07M	53.53M	53.36M	53.14M	52.67M
Weighted Average Basic & Diluted Shares Outstanding	49.41M	49.92M	49.69M	50.28M	49.91M	50.09M	51.90M	53.10M	53M	52.90M	52.20M

This table shows Prestige Consumer Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	50	61	54	49	49	53	54	53	-241	52	51
Consolidated Net Income / (Loss)	50	61	54	49	49	53	54	53	-241	52	51
Net Income / (Loss) Continuing Operations	50	61	54	49	49	53	54	53	-241	52	51
Total Pre-Tax Income	74	80	72	58	67	70	70	69	-300	68	67
Total Operating Income	88	92	84	72	82	87	88	85	-281	87	84
Total Gross Profit	170	161	157	146	152	158	160	155	154	150	161
Total Revenue	297	290	284	267	277	283	286	279	286	276	289
Operating Revenue	297	290	284	267	277	283	286	279	286	276	289
Total Cost of Revenue	127	129	126	121	125	125	126	125	132	125	128
Operating Cost of Revenue	127	129	126	121	125	125	126	125	132	125	128
Total Operating Expenses	82	69	73	74	70	71	72	69	435	63	77
Selling, General & Admin Expense	27	26	26	29	26	26	26	28	28	27	26
Marketing Expense	37	38	41	39	38	39	40	36	31	30	44
Depreciation Expense	5.06	4.96	5.57	5.70	5.68	5.64	5.67	5.56	6.01	6.26	6.37
Total Other Income / (Expense), net	-14	-12	-13	-14	-15	-17	-18	-16	-19	-19	-18
Interest Expense	11	11	12	13	15	17	18	18	19	18	17
Other Income / (Expense), net	-3.71	-0.35	-0.40	-0.50	0.43	-0.68	-0.23	1.24	0.45	-1.15	-0.81
Income Tax Expense	24	19	17	9.35	18	17	17	15	-59	16	16
Basic Earnings per Share	$1.01	$1.23	$1.10	$0.98	$0.99	$1.07	$1.08	$1.07	($4.82)	$1.05	$1.02
Weighted Average Basic Shares Outstanding	49.70M	49.60M	49.65M	49.89M	49.76M	49.74M	49.69M	49.77M	49.89M	49.69M	49.80M
Diluted Earnings per Share	$1.00	$1.22	$1.09	$0.98	$0.98	$1.06	$1.07	$1.06	($4.80)	$1.04	$1.02
Weighted Average Diluted Shares Outstanding	50.08M	49.99M	50.00M	50.27M	50.18M	50.13M	50.08M	50.20M	49.89M	50.19M	50.27M
Weighted Average Basic & Diluted Shares Outstanding	49.41M	49.54M	49.41M	49.56M	49.92M	49.65M	49.62M	49.54M	49.69M	49.69M	49.53M

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/31/2025	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016	3/31/2015
Net Change in Cash & Equivalents	51	-12	31	-5.12	-62	67	-5.02	-9.31	15	5.91	-7.01
Net Cash From Operating Activities	252	249	230	260	236	217	189	210	149	176	156
Net Cash From Continuing Operating Activities	252	249	230	260	236	217	189	210	149	176	156
Net Income / (Loss) Continuing Operations	215	209	-82	205	165	142	-36	340	69	100	78
Consolidated Net Income / (Loss)	215	209	-82	205	165	142	-36	340	69	100	78
Depreciation Expense	30	31	33	32	30	29	32	33	26	24	18
Amortization Expense	1.75	5.24	4.36	4.23	4.98	3.81	5.92	6.74	8.63	8.99	8.82
Non-Cash Adjustments To Reconcile Net Income	25	13	383	13	16	11	236	115	64	20	6.89
Changes in Operating Assets and Liabilities, net	-20	-9.63	-108	5.48	20	31	-49	-285	-19	24	45
Net Cash From Investing Activities	-17	-20	-12	-257	-22	-17	55	-12	-695	-223	-805
Net Cash From Continuing Investing Activities	-17	-20	-12	-257	-22	-17	55	-12	-695	-223	-805
Purchase of Property, Plant & Equipment	-8.22	-9.55	-7.78	-9.64	-22	-15	-10	-13	-2.98	-3.57	-6.10
Other Investing Activities, net	-9.23	-11	-	-247	0.00	0.75	0.00	0.97	-	-	-
Net Cash From Financing Activities	-182	-241	-186	-7.57	-279	-131	-249	-209	561	52	643
Net Cash From Continuing Financing Activities	-182	-241	-186	-7.57	-279	-131	-249	-209	561	52	643
Repayment of Debt	-135	-226	-155	-691	-883	-575	-245	-490	-979	-498	-205
Repurchase of Common Equity	-52	-25	-50	0.00	-12	-57	-50	0.00	0.00	-	-
Issuance of Debt	0.00	0.00	20	682	615	500	45	280	1,537	545	845
Other Financing Activities, net	4.43	9.75	-0.85	1.54	0.17	-0.13	0.65	0.55	2.60	4.47	3.18
Effect of Exchange Rate Changes	-0.57	-	-0.98	-	3.60	-1.89	-0.41	1.10	-	0.50	-1.28
Cash Interest Paid	48	63	54	61	80	92	98	99	85	79	70
Cash Income Taxes Paid	52	60	41	47	34	31	33	24	48	15	12

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	47	-0.67	17	-12	-17	3.55	5.49	-3.91	-28	44	6.57
Net Cash From Operating Activities	62	65	70	55	67	71	62	48	59	55	58
Net Cash From Continuing Operating Activities	62	65	70	55	67	71	62	48	59	55	58
Net Income / (Loss) Continuing Operations	50	61	54	49	49	53	54	53	-241	52	51
Consolidated Net Income / (Loss)	50	61	54	49	49	53	54	53	-241	52	51
Depreciation Expense	7.25	6.87	7.93	8.12	7.84	7.65	7.64	7.54	7.86	8.13	8.25
Amortization Expense	0.44	0.43	0.43	0.45	1.51	1.42	1.32	0.98	1.75	0.82	0.97
Non-Cash Adjustments To Reconcile Net Income	17	2.81	2.05	3.25	3.55	7.66	3.70	3.65	373	2.48	3.44
Changes in Operating Assets and Liabilities, net	-13	-6.05	5.02	-6.12	4.54	1.70	-3.76	-17	-83	-8.44	-6.14
Net Cash From Investing Activities	-3.48	-9.82	-2.03	-2.13	-15	-4.50	-2.93	2.32	-6.36	-1.80	-2.38
Net Cash From Continuing Investing Activities	-3.48	-9.82	-2.03	-2.13	-15	-4.50	-2.93	2.32	-6.36	-1.80	-2.38
Purchase of Property, Plant & Equipment	-3.48	-1.57	-2.03	-1.15	-3.14	-2.00	-2.93	-1.48	-2.56	-1.80	-2.38
Net Cash From Financing Activities	-11	-54	-51	-66	-68	-65	-54	-54	-80	-10	-48
Net Cash From Continuing Financing Activities	-11	-54	-51	-66	-68	-65	-54	-54	-80	-10	-48
Repurchase of Common Equity	-11	-2.40	-12	-26	-	-	-	-25	-	-	-12
Other Financing Activities, net	-0.18	8.54	0.62	-4.55	6.56	0.93	1.45	0.82	-0.50	4.98	-0.68
Effect of Exchange Rate Changes	0.13	-2.08	-	-	-	1.42	-0.49	-0.14	-	-	-
Cash Interest Paid	10	12	12	14	14	16	16	18	18	18	15
Cash Income Taxes Paid	19	15	15	3.66	21	13	13	12	13	12	14

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/31/2025	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016	3/31/2015
Total Assets	3,402	3,318	3,354	3,671	3,429	3,514	3,441	3,761	3,911	2,949	2,642
Total Current Assets	448	375	392	293	270	366	301	303	334	249	202
Cash & Equivalents	98	46	58	27	32	95	28	33	42	27	21
Accounts Receivable	194	177	167	139	115	151	149	141	137	95	88
Inventories, net	148	139	162	120	115	116	120	119	116	91	74
Prepaid Expenses	8.44	13	4.12	6.41	7.90	4.35	4.74	12	40	25	10
Plant, Property, & Equipment, net	75	77	70	71	70	56	51	53	51	16	14
Total Noncurrent Assets	2,879	2,867	2,892	3,306	3,089	3,092	3,089	3,405	3,526	2,684	2,427
Noncurrent Note & Lease Receivables	25	1.54	4.20	6.86	8.99	5.84	0.00	-	-	-	-
Goodwill	527	528	528	579	578	575	579	620	615	360	291
Intangible Assets	2,295	2,321	2,342	2,697	2,476	2,479	2,507	2,781	2,904	2,323	2,135
Other Noncurrent Operating Assets	32	17	18	24	27	32	3.13	3.57	7.45	1.32	1.17
Total Liabilities & Shareholders' Equity	3,402	3,318	3,354	3,671	3,429	3,514	3,441	3,761	3,911	2,949	2,642
Total Liabilities	1,567	1,663	1,907	2,093	2,071	2,343	2,345	2,582	3,089	2,204	2,014
Total Current Liabilities	107	117	161	143	122	150	127	123	162	107	99
Accounts Payable	19	39	63	56	46	62	57	61	70	38	46
Accrued Expenses	63	56	73	74	61	71	61	52	84	60	41
Dividends Payable	16	16	16	4.44	6.31	9.91	9.76	9.71	8.13	8.66	12
Other Current Liabilities	8.54	6.15	9.76	9.11	8.45	6.83	0.00	-	-	-	-
Total Noncurrent Liabilities	1,461	1,546	1,746	1,950	1,949	2,193	2,218	2,459	2,927	2,098	1,915
Long-Term Debt	992	1,126	1,346	1,477	1,480	1,730	1,799	1,993	2,194	1,625	1,561
Capital Lease Obligations	43	7.70	12	21	27	30	0.00	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	420	404	380	445	434	408	400	443	715	470	352
Other Noncurrent Operating Liabilities	5.39	9.19	8.17	7.48	8.61	25	20	23	18	2.84	2.46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,835	1,655	1,447	1,578	1,358	1,171	1,096	1,179	823	744	628
Total Preferred & Common Equity	1,835	1,655	1,447	1,578	1,358	1,171	1,096	1,179	823	744	628
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,835	1,655	1,447	1,578	1,358	1,171	1,096	1,179	823	744	628
Common Stock	594	568	536	516	500	489	480	469	459	446	427
Retained Earnings	1,556	1,341	1,132	1,214	1,009	844	702	736	397	327	227
Treasury Stock	-277	-220	-189	-134	-131	-118	-60	-7.67	-6.59	-5.16	-3.48
Accumulated Other Comprehensive Income / (Loss)	-38	-34	-32	-19	-20	-44	-26	-19	-26	-24	-23

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	12/31/2023	9/30/2023	6/30/2023	12/31/2022	9/30/2022	6/30/2022	12/31/2021
Total Assets	3,329	3,317	3,308	3,340	3,333	3,346	3,750	3,679	3,682	3,659
Total Current Assets	377	381	369	394	388	392	409	337	325	275
Cash & Equivalents	51	52	34	64	60	55	86	42	36	21
Accounts Receivable	167	164	172	174	158	158	157	146	145	134
Inventories, net	152	156	152	149	161	170	159	141	134	106
Prepaid Expenses	7.50	9.40	11	7.25	8.39	9.38	6.89	7.71	9.53	14
Plant, Property, & Equipment, net	74	75	75	70	71	70	70	70	70	70
Total Noncurrent Assets	2,879	2,861	2,863	2,876	2,874	2,884	3,271	3,272	3,287	3,285
Noncurrent Note & Lease Receivables	4.94	0.21	0.88	2.21	2.87	3.54	4.86	5.53	6.19	-
Goodwill	527	529	528	528	527	527	577	576	577	579
Intangible Assets	2,311	2,317	2,318	2,329	2,328	2,336	2,670	2,671	2,683	2,704
Other Noncurrent Operating Assets	36	15	16	17	16	17	20	20	22	2.89
Total Liabilities & Shareholders' Equity	3,329	3,317	3,308	3,340	3,333	3,346	3,750	3,679	3,682	3,659
Total Liabilities	1,541	1,585	1,627	1,739	1,797	1,865	2,063	2,059	2,097	2,141
Total Current Liabilities	103	107	114	127	130	147	160	152	155	135
Accounts Payable	20	31	40	39	44	58	64	56	58	40
Accrued Expenses	61	57	55	65	60	65	71	71	73	71
Dividends Payable	15	16	15	15	16	15	15	16	15	15
Other Current Liabilities	6.92	2.65	4.45	7.84	9.61	9.46	9.67	9.44	9.32	-
Total Noncurrent Liabilities	1,439	1,478	1,513	1,612	1,667	1,718	1,903	1,906	1,942	453
Long-Term Debt	992	1,052	1,091	1,199	1,263	1,317	1,424	1,438	1,472	-
Capital Lease Obligations	28	0.13	7.20	6.33	0.22	9.16	14	3.09	3.80	-
Noncurrent Deferred & Payable Income Tax Liabilities	413	415	409	397	388	384	456	443	443	445
Other Noncurrent Operating Liabilities	5.03	12	5.14	8.92	16	8.18	8.87	22	23	8.43
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,788	1,732	1,681	1,601	1,536	1,480	1,687	1,620	1,585	1,518
Total Preferred & Common Equity	1,788	1,732	1,681	1,601	1,536	1,480	1,687	1,620	1,585	1,518
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,788	1,732	1,681	1,601	1,536	1,480	1,687	1,620	1,585	1,518
Common Stock	589	577	573	557	553	547	533	525	521	513
Retained Earnings	1,506	1,445	1,390	1,292	1,239	1,185	1,372	1,320	1,269	1,162
Treasury Stock	-266	-263	-252	-220	-220	-220	-189	-189	-177	-134
Accumulated Other Comprehensive Income / (Loss)	-40	-27	-31	-29	-36	-32	-29	-36	-29	-23

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/31/2025	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016	3/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.10%	-0.21%	3.76%	15.21%	-2.04%	-1.31%	-68.76%	254.12%	9.40%	12.82%	19.63%
EBITDA Growth	-4.05%	2,997.73%	-96.65%	9.37%	3.59%	207.78%	-59.10%	6.66%	-18.07%	24.54%	10.65%
EBIT Growth	-3.31%	1,486.55%	-107.53%	10.07%	3.19%	331.96%	-68.95%	4.99%	-21.01%	24.74%	10.64%
NOPAT Growth	-2.07%	1,755.14%	-106.08%	7.59%	10.72%	358.64%	-93.08%	430.74%	-22.19%	29.83%	-5.33%
Net Income Growth	2.52%	354.34%	-140.07%	24.71%	15.74%	497.43%	-110.54%	389.33%	-30.54%	27.66%	7.77%
EPS Growth	2.88%	352.73%	-140.84%	24.31%	16.91%	502.90%	-110.88%	387.69%	-30.85%	26.17%	7.19%
Operating Cash Flow Growth	1.04%	8.36%	-11.62%	10.32%	8.51%	14.71%	-9.91%	41.32%	-15.68%	12.83%	40.04%
Free Cash Flow Firm Growth	-15.06%	-4.14%	516.93%	-81.99%	-0.02%	-22.51%	-38.25%	202.86%	-8,194.20%	98.94%	-658.47%
Invested Capital Growth	1.11%	-0.14%	-9.52%	7.53%	-0.26%	-1.07%	-8.64%	5.57%	26.86%	7.87%	47.36%
Revenue Q/Q Growth	1.75%	-0.78%	1.71%	2.76%	-1.69%	106.12%	-72.56%	204.47%	3.86%	2.26%	7.04%
EBITDA Q/Q Growth	0.13%	2,235.94%	-96.69%	1.73%	2.55%	205.15%	-55.68%	-22.74%	-4.90%	1.77%	10.04%
EBIT Q/Q Growth	0.65%	1,820.83%	-107.44%	1.62%	2.66%	300.47%	-66.06%	-25.99%	-5.61%	1.57%	9.11%
NOPAT Q/Q Growth	-0.17%	1,890.46%	-105.92%	2.25%	6.28%	327.49%	-66.90%	7.10%	-4.57%	0.02%	10.32%
Net Income Q/Q Growth	0.31%	359.50%	-139.13%	8.78%	5.27%	686.53%	-156.12%	-13.01%	-3.94%	-8.96%	11.02%
EPS Q/Q Growth	0.47%	359.01%	-139.57%	8.60%	5.86%	795.00%	-156.10%	-13.03%	-3.70%	-9.62%	12.03%
Operating Cash Flow Q/Q Growth	-1.97%	3.29%	-1.77%	1.58%	1.27%	2.49%	-1.86%	28.75%	-17.86%	-6.50%	15.86%
Free Cash Flow Firm Q/Q Growth	-6.61%	-6.41%	7.14%	13.03%	4.24%	-8.82%	2.22%	218.73%	-589.49%	-102.21%	15.65%
Invested Capital Q/Q Growth	0.56%	0.00%	-9.57%	0.23%	0.22%	0.08%	-6.13%	-2.64%	38.05%	10.46%	-2.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.76%	55.49%	55.45%	57.11%	58.03%	57.34%	56.94%	18.46%	56.72%	57.95%	56.84%
EBITDA Margin	31.97%	33.69%	1.09%	33.60%	35.40%	33.47%	10.73%	8.20%	27.21%	36.34%	32.92%
Operating Margin	29.60%	30.43%	-1.99%	30.36%	31.53%	30.23%	6.92%	6.90%	23.31%	32.29%	29.04%
EBIT Margin	29.16%	30.50%	-2.19%	30.26%	31.67%	30.07%	6.87%	6.91%	23.31%	32.29%	29.20%
Profit (Net Income) Margin	18.86%	18.60%	-7.30%	18.90%	17.46%	14.77%	-3.67%	10.87%	7.87%	12.39%	10.95%
Tax Burden Percent	75.51%	75.84%	87.64%	78.25%	80.68%	74.43%	94.07%	317.10%	62.60%	63.56%	61.40%
Interest Burden Percent	85.65%	80.43%	379.44%	79.81%	68.32%	66.02%	-56.78%	49.61%	53.91%	60.38%	61.07%
Effective Tax Rate	24.49%	24.16%	0.00%	21.75%	19.32%	25.57%	0.00%	-217.10%	37.40%	36.44%	38.60%
Return on Invested Capital (ROIC)	9.17%	9.41%	-0.54%	8.77%	8.44%	7.57%	1.57%	22.29%	4.83%	7.30%	6.97%
ROIC Less NNEP Spread (ROIC-NNEP)	5.31%	5.24%	-5.32%	5.19%	3.67%	3.27%	-2.86%	5.64%	1.68%	3.15%	2.98%
Return on Net Nonoperating Assets (RNNOA)	3.13%	4.09%	-4.90%	5.23%	4.58%	4.98%	-4.72%	11.65%	4.03%	7.26%	6.18%
Return on Equity (ROE)	12.30%	13.50%	-5.44%	13.99%	13.02%	12.55%	-3.15%	33.94%	8.86%	14.56%	13.14%
Cash Return on Invested Capital (CROIC)	8.07%	9.55%	9.45%	1.51%	8.70%	8.65%	10.60%	16.87%	-18.85%	-0.27%	-31.33%
Operating Return on Assets (OROA)	9.87%	10.29%	-0.70%	9.26%	8.61%	8.33%	1.86%	5.63%	5.99%	9.31%	9.41%
Return on Assets (ROA)	6.39%	6.28%	-2.34%	5.79%	4.74%	4.09%	-0.99%	8.85%	2.02%	3.57%	3.53%
Return on Common Equity (ROCE)	12.30%	13.50%	-5.44%	13.99%	13.02%	12.55%	-3.15%	33.94%	8.86%	14.56%	13.14%
Return on Equity Simple (ROE_SIMPLE)	11.70%	12.65%	-5.69%	13.02%	12.12%	12.15%	-3.27%	28.81%	8.44%	13.42%	12.47%
Net Operating Profit after Tax (NOPAT)	254	260	-16	258	240	217	47	683	129	165	127
NOPAT Margin	22.35%	23.08%	-1.39%	23.75%	25.44%	22.50%	4.84%	21.87%	14.60%	20.52%	17.83%
Net Nonoperating Expense Percent (NNEP)	3.86%	4.17%	4.78%	3.57%	4.77%	4.31%	4.43%	16.64%	3.15%	4.15%	3.99%
Return On Investment Capital (ROIC_SIMPLE)	8.86%	-	-	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	44.24%	44.51%	44.55%	42.89%	41.97%	42.66%	43.06%	14.88%	43.28%	42.05%	43.16%
SG&A Expenses to Revenue	9.51%	9.43%	9.52%	9.89%	8.81%	9.25%	9.20%	2.73%	10.10%	8.98%	11.37%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	26.16%	25.06%	57.44%	26.75%	26.51%	27.11%	50.02%	11.56%	33.40%	25.66%	27.80%
Earnings before Interest and Taxes (EBIT)	332	343	-25	329	299	290	67	216	206	260	209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	364	379	12	365	334	322	105	256	240	293	235
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.32	2.18	2.15	1.68	1.62	1.57	1.41	1.50	3.53	3.74	3.53
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.74	3.20	2.76	2.45	2.33	1.91	1.59	0.57	3.29	3.45	3.10
Price to Earnings (P/E)	19.84	17.21	0.00	12.94	13.35	12.96	0.00	0.73	41.86	27.84	28.30
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.59%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.04%	5.81%	0.00%	7.73%	7.49%	7.72%	0.00%	137.11%	2.39%	3.59%	3.53%
Enterprise Value to Invested Capital (EV/IC)	1.86	1.70	1.60	1.35	1.29	1.23	1.15	1.18	1.70	1.86	1.72
Enterprise Value to Revenue (EV/Rev)	4.57	4.17	3.91	3.80	3.89	3.64	3.40	1.19	5.73	5.43	5.25
Enterprise Value to EBITDA (EV/EBITDA)	14.29	12.37	360.42	11.30	11.00	10.89	31.70	14.56	21.07	14.95	15.96
Enterprise Value to EBIT (EV/EBIT)	15.66	13.66	0.00	12.55	12.29	12.12	49.54	17.26	24.59	16.83	17.99
Enterprise Value to NOPAT (EV/NOPAT)	20.43	18.06	0.00	15.99	15.30	16.19	70.27	5.45	39.28	26.47	29.46
Enterprise Value to Operating Cash Flow (EV/OCF)	20.66	18.84	19.20	15.88	15.58	16.16	17.54	17.74	34.01	24.84	24.03
Enterprise Value to Free Cash Flow (EV/FCFF)	23.22	17.80	16.05	92.66	14.84	14.18	10.40	7.21	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.56	0.68	0.94	0.95	1.11	1.50	1.64	1.69	2.67	2.18	2.49
Long-Term Debt to Equity	0.56	0.68	0.94	0.95	1.11	1.50	1.64	1.69	2.67	2.18	2.49
Financial Leverage	0.59	0.78	0.92	1.01	1.25	1.52	1.65	2.06	2.40	2.30	2.07
Leverage Ratio	1.93	2.15	2.32	2.42	2.75	3.07	3.17	3.83	4.38	4.08	3.73
Compound Leverage Factor	1.65	1.73	8.81	1.93	1.88	2.03	-1.80	1.90	2.36	2.46	2.28
Debt to Total Capital	36.08%	40.65%	48.40%	48.69%	52.58%	60.05%	62.14%	62.84%	72.73%	68.59%	71.33%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	36.08%	40.65%	48.40%	48.69%	52.58%	60.05%	62.14%	62.84%	72.73%	68.59%	71.33%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.92%	59.35%	51.60%	51.31%	47.42%	39.95%	37.86%	37.16%	27.27%	31.41%	28.67%
Debt to EBITDA	2.85	2.99	110.91	4.10	4.51	5.46	17.17	7.78	9.14	5.55	6.64
Net Debt to EBITDA	2.58	2.87	106.13	4.03	4.41	5.17	16.91	7.66	8.96	5.45	6.55
Long-Term Debt to EBITDA	2.85	2.99	110.91	4.10	4.51	5.46	17.17	7.78	9.14	5.55	6.64
Debt to NOPAT	4.07	4.36	-86.51	5.80	6.28	8.12	38.06	2.92	17.04	9.82	12.25
Net Debt to NOPAT	3.69	4.19	-82.78	5.69	6.14	7.68	37.48	2.87	16.72	9.66	12.08
Long-Term Debt to NOPAT	4.07	4.36	-86.51	5.80	6.28	8.12	38.06	2.92	17.04	9.82	12.25
Altman Z-Score	3.05	2.64	1.85	1.87	1.66	1.43	1.09	1.76	1.16	1.54	1.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.20	3.20	2.44	2.04	2.21	2.44	2.37	2.46	2.06	2.33	2.04
Quick Ratio	2.74	1.91	1.40	1.16	1.20	1.64	1.39	1.41	1.10	1.15	1.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	224	263	275	45	247	247	319	517	-503	-6.06	-573
Operating Cash Flow to CapEx	3,058.31%	2,606.56%	2,951.13%	2,695.73%	1,059.24%	1,491.24%	1,806.15%	1,676.59%	5,140.80%	5,468.67%	0.00%
Free Cash Flow to Firm to Interest Expense	4.70	3.92	3.97	0.67	2.61	2.52	3.04	4.74	-5.29	-0.06	-7.05
Operating Cash Flow to Interest Expense	5.28	3.71	3.32	3.91	2.49	2.21	1.80	1.92	1.57	1.71	1.92
Operating Cash Flow Less CapEx to Interest Expense	5.11	3.56	3.21	3.77	2.25	2.06	1.70	1.81	1.54	1.68	1.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.34	0.32	0.31	0.27	0.28	0.27	0.81	0.26	0.29	0.32
Accounts Receivable Turnover	6.13	6.55	7.36	8.56	7.11	6.44	6.74	22.50	7.60	8.81	9.35
Inventory Turnover	3.51	3.33	3.56	3.96	3.43	3.48	3.52	3.97	3.69	4.10	4.42
Fixed Asset Turnover	15.06	15.32	15.92	15.38	14.97	17.97	18.81	60.56	26.67	55.06	61.23
Accounts Payable Turnover	17.38	9.85	8.48	9.16	7.31	6.91	7.13	7.06	7.04	8.03	6.53
Days Sales Outstanding (DSO)	59.52	55.75	49.58	42.65	51.30	56.72	54.18	16.22	48.00	41.45	39.05
Days Inventory Outstanding (DIO)	103.86	109.61	102.60	92.12	106.48	104.81	103.55	91.96	98.89	88.96	82.60
Days Payable Outstanding (DPO)	21.00	37.06	43.04	39.83	49.95	52.84	51.23	51.69	51.87	45.44	55.86
Cash Conversion Cycle (CCC)	142.38	128.30	109.13	94.94	107.83	108.69	106.50	56.50	95.02	84.97	65.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,788	2,758	2,762	3,052	2,838	2,846	2,877	3,149	2,983	2,351	2,180
Invested Capital Turnover	0.41	0.41	0.39	0.37	0.33	0.34	0.32	1.02	0.33	0.36	0.39
Increase / (Decrease) in Invested Capital	31	-3.73	-290	214	-7.44	-31	-272	166	631	172	700
Enterprise Value (EV)	5,197	4,690	4,411	4,128	3,672	3,509	3,320	3,727	5,057	4,380	3,754
Market Capitalization	4,259	3,603	3,112	2,658	2,198	1,844	1,549	1,766	2,905	2,782	2,214
Book Value per Share	$37.04	$33.34	$29.12	$31.43	$27.24	$23.30	$21.16	$22.22	$15.54	$14.11	$12.01
Tangible Book Value per Share	($19.94)	($24.03)	($28.63)	($33.83)	($34.00)	($37.47)	($38.42)	($41.90)	($50.94)	($36.75)	($34.39)
Total Capital	2,871	2,789	2,804	3,075	2,864	2,931	2,894	3,172	3,016	2,370	2,189
Total Debt	1,036	1,134	1,357	1,497	1,506	1,760	1,799	1,993	2,194	1,625	1,561
Total Long-Term Debt	1,036	1,134	1,357	1,497	1,506	1,760	1,799	1,993	2,194	1,625	1,561
Net Debt	938	1,087	1,299	1,470	1,474	1,665	1,771	1,960	2,152	1,598	1,540
Capital Expenditures (CapEx)	8.22	9.55	7.78	9.64	22	15	10	13	2.89	3.22	-3.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)	244	212	173	123	115	121	146	148	131	115	81
Debt-free Net Working Capital (DFNWC)	342	258	231	150	148	216	174	180	172	142	103
Net Working Capital (NWC)	342	258	231	150	148	216	174	180	172	142	103
Net Nonoperating Expense (NNE)	40	50	67	53	75	74	83	344	59	66	49
Net Nonoperating Obligations (NNO)	954	1,103	1,315	1,474	1,480	1,675	1,781	1,970	2,160	1,607	1,552
Total Depreciation and Amortization (D&A)	32	36	37	36	35	33	38	40	34	33	27
Debt-free, Cash-free Net Working Capital to Revenue	21.43%	18.80%	15.30%	11.29%	12.23%	12.57%	15.01%	4.73%	14.80%	14.28%	11.38%
Debt-free Net Working Capital to Revenue	30.03%	22.93%	20.49%	13.79%	15.66%	22.41%	17.83%	5.77%	19.55%	17.65%	14.37%
Net Working Capital to Revenue	30.03%	22.93%	20.49%	13.79%	15.66%	22.41%	17.83%	5.77%	19.55%	17.65%	14.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.32	$4.21	($1.65)	$4.09	$3.28	$2.81	($0.69)	$6.40	$1.31	$1.89	$1.50
Adjusted Weighted Average Basic Shares Outstanding	49.70M	49.76M	49.89M	50.26M	50.21M	50.72M	52.07M	53.10M	52.98M	52.75M	52.17M
Adjusted Diluted Earnings per Share	$4.29	$4.17	($1.65)	$4.04	$3.25	$2.78	($0.69)	$6.34	$1.30	$1.88	$1.49
Adjusted Weighted Average Diluted Shares Outstanding	50.08M	50.18M	49.89M	50.84M	50.61M	51.14M	52.07M	53.53M	53.36M	53.14M	52.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.69)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.41M	49.92M	49.69M	50.28M	49.91M	50.09M	51.80M	53.07M	52.96M	52.76M	52.30M
Normalized Net Operating Profit after Tax (NOPAT)	264	260	243	259	242	217	208	221	129	165	127
Normalized NOPAT Margin	23.18%	23.08%	21.59%	23.83%	25.64%	22.50%	21.30%	7.07%	14.60%	20.52%	17.83%
Pre Tax Income Margin	24.98%	24.53%	-8.33%	24.15%	21.64%	19.85%	-3.90%	3.43%	12.57%	19.50%	17.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	6.97	5.11	-0.36	4.95	3.16	2.94	0.64	1.98	2.17	2.52	2.57
NOPAT to Interest Expense	5.34	3.87	-0.23	3.89	2.54	2.20	0.45	6.26	1.36	1.60	1.57
EBIT Less CapEx to Interest Expense	6.79	4.97	-0.47	4.81	2.92	2.80	0.54	1.86	2.13	2.49	2.61
NOPAT Less CapEx to Interest Expense	5.17	3.72	-0.34	3.74	2.30	2.05	0.35	6.14	1.33	1.57	1.62
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	24.00%	11.94%	-60.75%	0.00%	7.21%	39.87%	-139.60%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.05%	2.68%	-0.88%	-4.36%	-3.11%	2.62%	-1.02%	0.81%	7.09%	0.38%	4.72%
EBITDA Growth	0.51%	3.88%	-4.83%	-15.62%	133.93%	0.25%	4.52%	-0.46%	-411.98%	3.41%	7.02%
EBIT Growth	2.59%	6.34%	-4.63%	-17.22%	129.44%	0.13%	5.32%	0.28%	-464.64%	4.39%	7.05%
NOPAT Growth	-0.69%	5.77%	-4.66%	-8.38%	130.68%	-0.44%	3.82%	-2.63%	-397.36%	5.00%	8.28%
Net Income Growth	1.35%	15.05%	1.53%	-7.90%	120.56%	2.11%	4.97%	-3.61%	-561.84%	3.46%	12.57%
EPS Growth	2.04%	15.09%	1.87%	-7.55%	120.42%	1.92%	4.90%	-2.75%	-570.59%	5.05%	14.61%
Operating Cash Flow Growth	-7.56%	-8.93%	11.75%	13.91%	13.43%	30.09%	8.55%	-17.44%	-6.56%	-17.13%	-5.97%
Free Cash Flow Firm Growth	-54.14%	-84.85%	-79.51%	-80.23%	-31.68%	525.76%	429.85%	315.73%	163.60%	138.65%	138.88%
Invested Capital Growth	1.11%	0.55%	-0.26%	-0.24%	-0.14%	-9.69%	-9.22%	-9.00%	-9.52%	0.28%	-0.03%
Revenue Q/Q Growth	2.14%	2.30%	6.23%	-3.56%	-2.03%	-1.25%	2.51%	-2.29%	3.75%	-4.75%	4.41%
EBITDA Q/Q Growth	-6.57%	7.16%	15.19%	-12.85%	-3.45%	-1.82%	2.13%	135.05%	-385.25%	2.36%	-2.74%
EBIT Q/Q Growth	-7.52%	9.13%	17.32%	-13.36%	-4.14%	-2.13%	1.84%	130.81%	-426.09%	2.95%	-3.04%
NOPAT Q/Q Growth	-14.41%	9.42%	5.74%	0.28%	-8.84%	-1.37%	1.62%	133.58%	-395.82%	2.84%	-4.69%
Net Income Q/Q Growth	-17.87%	12.24%	10.82%	-0.79%	-6.76%	-0.96%	0.53%	122.15%	-563.04%	1.82%	-7.69%
EPS Q/Q Growth	-18.03%	11.93%	11.22%	0.00%	-7.55%	-0.93%	0.94%	122.08%	-561.54%	1.96%	-6.42%
Operating Cash Flow Q/Q Growth	-4.98%	-6.75%	27.43%	-18.13%	-6.39%	14.43%	29.89%	-18.48%	7.36%	-4.52%	-1.21%
Free Cash Flow Firm Q/Q Growth	-46.45%	-22.79%	5.88%	4.74%	-82.31%	4.40%	2.17%	262.01%	62.06%	-11.60%	141.60%
Invested Capital Q/Q Growth	0.56%	0.92%	-0.45%	0.08%	0.00%	0.11%	-0.44%	0.19%	-9.57%	0.64%	-0.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	57.34%	55.47%	55.46%	54.66%	54.81%	55.86%	55.89%	55.38%	53.79%	54.59%	55.66%
EBITDA Margin	31.16%	34.07%	32.53%	29.99%	33.19%	33.68%	33.87%	34.00%	-94.77%	34.47%	32.08%
Operating Margin	29.82%	31.68%	29.72%	26.97%	29.66%	30.71%	30.82%	30.50%	-98.30%	31.64%	29.17%
EBIT Margin	28.57%	31.55%	29.58%	26.78%	29.81%	30.47%	30.74%	30.94%	-98.14%	31.23%	28.89%
Profit (Net Income) Margin	16.91%	21.02%	19.16%	18.37%	17.86%	18.76%	18.71%	19.07%	-84.15%	18.86%	17.64%
Tax Burden Percent	67.78%	76.14%	75.88%	84.00%	73.46%	76.24%	76.06%	77.53%	80.31%	76.27%	76.62%
Interest Burden Percent	87.30%	87.50%	85.37%	81.64%	81.52%	80.76%	80.00%	79.50%	106.76%	79.17%	79.68%
Effective Tax Rate	32.22%	23.86%	24.12%	16.00%	26.54%	23.76%	23.94%	22.47%	0.00%	23.73%	23.38%
Return on Invested Capital (ROIC)	8.29%	9.75%	9.10%	9.13%	8.89%	9.14%	9.13%	9.20%	-26.69%	8.77%	8.16%
ROIC Less NNEP Spread (ROIC-NNEP)	7.34%	8.91%	8.24%	8.16%	7.98%	8.10%	8.10%	8.27%	-29.84%	7.77%	7.25%
Return on Net Nonoperating Assets (RNNOA)	4.32%	5.63%	5.64%	6.11%	6.22%	6.22%	6.76%	7.40%	-27.51%	7.02%	7.03%
Return on Equity (ROE)	12.62%	15.39%	14.74%	15.23%	15.11%	15.36%	15.89%	16.60%	-54.21%	15.79%	15.18%
Cash Return on Invested Capital (CROIC)	8.07%	8.66%	9.38%	9.44%	9.55%	9.69%	9.17%	8.84%	9.45%	8.41%	8.66%
Operating Return on Assets (OROA)	9.67%	10.58%	9.88%	8.96%	10.06%	9.75%	9.88%	9.95%	-31.51%	9.35%	8.70%
Return on Assets (ROA)	5.72%	7.05%	6.40%	6.15%	6.02%	6.00%	6.01%	6.13%	-27.02%	5.64%	5.31%
Return on Common Equity (ROCE)	12.62%	15.39%	14.74%	15.23%	15.11%	15.36%	15.89%	16.60%	-54.21%	15.79%	15.18%
Return on Equity Simple (ROE_SIMPLE)	0.00%	11.96%	11.89%	12.20%	0.00%	-5.04%	-5.32%	-5.69%	0.00%	12.47%	12.88%
Net Operating Profit after Tax (NOPAT)	60	70	64	61	60	66	67	66	-197	66	65
NOPAT Margin	20.21%	24.12%	22.55%	22.65%	21.79%	23.41%	23.44%	23.65%	-68.81%	24.13%	22.35%
Net Nonoperating Expense Percent (NNEP)	0.95%	0.84%	0.86%	0.97%	0.90%	1.04%	1.03%	0.93%	3.14%	1.01%	0.91%
Return On Investment Capital (ROIC_SIMPLE)	2.09%	2.49%	-	-	-	2.36%	-	-	-	-	-
Cost of Revenue to Revenue	42.66%	44.53%	44.54%	45.34%	45.19%	44.14%	44.11%	44.62%	46.21%	45.41%	44.34%
SG&A Expenses to Revenue	9.12%	9.02%	9.19%	10.82%	9.55%	9.20%	9.08%	9.91%	9.68%	9.63%	9.14%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.51%	23.80%	25.74%	27.69%	25.15%	25.15%	25.07%	24.88%	152.08%	22.94%	26.49%
Earnings before Interest and Taxes (EBIT)	85	92	84	72	83	86	88	86	-281	86	84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	92	99	92	80	92	95	97	95	-271	95	93
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.32	2.16	2.06	2.04	2.18	1.90	1.84	2.00	2.15	1.84	1.53
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.74	3.45	3.22	3.09	3.20	2.68	2.51	2.61	2.76	2.80	2.24
Price to Earnings (P/E)	19.84	18.03	17.35	16.75	17.21	0.00	0.00	0.00	0.00	14.74	11.89
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.04%	5.55%	5.76%	5.97%	5.81%	0.00%	0.00%	0.00%	0.00%	6.78%	8.41%
Enterprise Value to Invested Capital (EV/IC)	1.86	1.74	1.66	1.63	1.70	1.52	1.47	1.53	1.60	1.46	1.28
Enterprise Value to Revenue (EV/Rev)	4.57	4.32	4.12	4.04	4.17	3.69	3.58	3.74	3.91	4.02	3.50
Enterprise Value to EBITDA (EV/EBITDA)	14.29	13.29	12.72	12.36	12.37	257.55	252.46	358.16	360.42	12.03	10.57
Enterprise Value to EBIT (EV/EBIT)	15.66	14.64	14.11	13.71	13.66	0.00	0.00	0.00	0.00	13.38	11.79
Enterprise Value to NOPAT (EV/NOPAT)	20.43	18.95	18.22	17.71	18.06	0.00	0.00	0.00	0.00	16.79	14.81
Enterprise Value to Operating Cash Flow (EV/OCF)	20.66	18.81	17.39	17.61	18.84	17.34	17.98	19.24	19.20	19.04	15.82
Enterprise Value to Free Cash Flow (EV/FCFF)	23.22	20.15	17.72	17.26	17.80	14.85	15.20	16.47	16.05	17.36	14.76
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.56	0.57	0.61	0.65	0.68	0.75	0.82	0.90	0.94	0.85	0.89
Long-Term Debt to Equity	0.56	0.57	0.61	0.65	0.68	0.75	0.82	0.90	0.94	0.85	0.89
Financial Leverage	0.59	0.63	0.68	0.75	0.78	0.77	0.83	0.89	0.92	0.90	0.97
Leverage Ratio	1.93	1.97	2.04	2.10	2.15	2.16	2.22	2.29	2.32	2.31	2.39
Compound Leverage Factor	1.68	1.72	1.74	1.72	1.75	1.74	1.78	1.82	2.48	1.83	1.90
Debt to Total Capital	36.08%	36.32%	37.78%	39.52%	40.65%	42.96%	45.13%	47.25%	48.40%	46.02%	47.09%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	36.08%	36.32%	37.78%	39.52%	40.65%	42.96%	45.13%	47.25%	48.40%	46.02%	47.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.92%	63.68%	62.22%	60.48%	59.35%	57.04%	54.87%	52.75%	51.60%	53.98%	52.91%
Debt to EBITDA	2.85	2.81	2.92	3.02	2.99	74.29	79.01	112.41	110.91	3.89	3.93
Net Debt to EBITDA	2.58	2.67	2.78	2.92	2.87	70.37	75.25	107.78	106.13	3.65	3.81
Long-Term Debt to EBITDA	2.85	2.81	2.92	3.02	2.99	74.29	79.01	112.41	110.91	3.89	3.93
Debt to NOPAT	4.07	4.00	4.19	4.32	4.36	-83.12	-88.59	-78.16	-86.51	5.42	5.50
Net Debt to NOPAT	3.69	3.81	3.98	4.19	4.19	-78.74	-84.38	-74.94	-82.78	5.10	5.34
Long-Term Debt to NOPAT	4.07	4.00	4.19	4.32	4.36	-83.12	-88.59	-78.16	-86.51	5.42	5.50
Altman Z-Score	2.81	2.66	2.48	2.36	2.38	2.11	1.98	1.96	1.59	1.87	1.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.20	3.68	3.56	3.23	3.20	3.09	2.99	2.66	2.44	2.55	2.21
Quick Ratio	2.74	2.13	2.01	1.80	1.91	1.87	1.68	1.44	1.40	1.52	1.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	29	55	71	67	64	362	347	340	94	58	65
Operating Cash Flow to CapEx	1,777.75%	4,156.51%	3,443.51%	4,754.86%	2,128.76%	3,580.76%	2,128.83%	3,255.72%	2,305.98%	3,047.25%	2,421.72%
Free Cash Flow to Firm to Interest Expense	2.73	4.79	5.79	5.11	4.20	21.85	19.71	19.16	4.94	3.23	3.86
Operating Cash Flow to Interest Expense	5.75	5.68	5.68	4.17	4.38	4.31	3.55	2.71	3.11	3.07	3.39
Operating Cash Flow Less CapEx to Interest Expense	5.43	5.55	5.52	4.08	4.18	4.19	3.38	2.63	2.97	2.97	3.25
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.34	0.33	0.33	0.34	0.32	0.32	0.32	0.32	0.30	0.30
Accounts Receivable Turnover	6.13	6.55	6.90	6.75	6.55	6.85	7.40	7.45	7.36	7.61	7.57
Inventory Turnover	3.51	3.34	3.13	3.09	3.33	3.31	3.37	3.36	3.56	3.69	3.89
Fixed Asset Turnover	15.06	15.54	15.25	15.31	15.32	16.21	16.03	16.10	15.92	15.91	15.83
Accounts Payable Turnover	17.38	17.06	13.17	10.21	9.85	9.80	10.10	8.80	8.48	9.36	10.24
Days Sales Outstanding (DSO)	59.52	55.74	52.91	54.04	55.75	53.32	49.30	49.00	49.58	47.95	48.20
Days Inventory Outstanding (DIO)	103.86	109.13	116.47	118.11	109.61	110.38	108.38	108.62	102.60	98.95	93.93
Days Payable Outstanding (DPO)	21.00	21.39	27.72	35.74	37.06	37.23	36.12	41.49	43.04	39.00	35.63
Cash Conversion Cycle (CCC)	142.38	143.48	141.67	136.40	128.30	126.47	121.56	116.13	109.13	107.90	106.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,788	2,773	2,748	2,760	2,758	2,758	2,755	2,767	2,762	3,054	3,035
Invested Capital Turnover	0.41	0.40	0.40	0.40	0.41	0.39	0.39	0.39	0.39	0.36	0.37
Increase / (Decrease) in Invested Capital	31	15	-7.08	-6.61	-3.73	-296	-280	-274	-290	8.61	-0.82
Enterprise Value (EV)	5,197	4,827	4,573	4,501	4,690	4,180	4,036	4,225	4,411	4,452	3,879
Market Capitalization	4,259	3,858	3,573	3,437	3,603	3,038	2,833	2,953	3,112	3,100	2,480
Book Value per Share	$37.04	$36.20	$34.94	$33.67	$33.34	$32.26	$31.00	$29.79	$29.12	$34.06	$32.55
Tangible Book Value per Share	($19.94)	($21.24)	($22.48)	($23.35)	($24.03)	($25.31)	($26.63)	($27.84)	($28.63)	($31.50)	($32.69)
Total Capital	2,871	2,809	2,783	2,779	2,789	2,806	2,799	2,806	2,804	3,125	3,061
Total Debt	1,036	1,020	1,052	1,098	1,134	1,206	1,263	1,326	1,357	1,438	1,441
Total Long-Term Debt	1,036	1,020	1,052	1,098	1,134	1,206	1,263	1,326	1,357	1,438	1,441
Net Debt	938	969	1,000	1,064	1,087	1,142	1,203	1,271	1,299	1,352	1,399
Capital Expenditures (CapEx)	3.48	1.57	2.03	1.15	3.14	2.00	2.93	1.48	2.56	1.80	2.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	244	224	222	220	212	203	198	190	173	162	142
Debt-free Net Working Capital (DFNWC)	342	275	274	255	258	266	258	244	231	249	184
Net Working Capital (NWC)	342	275	274	255	258	266	258	244	231	249	184
Net Nonoperating Expense (NNE)	9.81	8.99	9.62	11	11	13	14	13	44	15	14
Net Nonoperating Obligations (NNO)	954	985	1,016	1,079	1,103	1,157	1,219	1,286	1,315	1,367	1,415
Total Depreciation and Amortization (D&A)	7.69	7.30	8.36	8.58	9.36	9.07	8.96	8.53	9.61	8.95	9.22
Debt-free, Cash-free Net Working Capital to Revenue	21.43%	20.01%	20.01%	19.80%	18.80%	17.87%	17.61%	16.81%	15.30%	14.64%	12.81%
Debt-free Net Working Capital to Revenue	30.03%	24.56%	24.65%	22.87%	22.93%	23.48%	22.94%	21.64%	20.49%	22.43%	16.64%
Net Working Capital to Revenue	30.03%	24.56%	24.65%	22.87%	22.93%	23.48%	22.94%	21.64%	20.49%	22.43%	16.64%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.01	$1.23	$1.10	$0.98	$0.99	$1.07	$1.08	$1.07	($4.82)	$1.05	$1.02
Adjusted Weighted Average Basic Shares Outstanding	49.70M	49.60M	49.65M	49.89M	49.76M	49.74M	49.69M	49.77M	49.89M	49.69M	49.80M
Adjusted Diluted Earnings per Share	$1.00	$1.22	$1.09	$0.98	$0.98	$1.06	$1.07	$1.06	($4.80)	$1.04	$1.02
Adjusted Weighted Average Diluted Shares Outstanding	50.08M	49.99M	50.00M	50.27M	50.18M	50.13M	50.08M	50.20M	49.89M	50.19M	50.27M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.41M	49.54M	49.41M	49.56M	49.92M	49.65M	49.62M	49.54M	49.69M	49.69M	49.53M
Normalized Net Operating Profit after Tax (NOPAT)	60	70	64	61	60	66	67	66	-197	66	65
Normalized NOPAT Margin	20.21%	24.12%	22.55%	22.65%	21.79%	23.41%	23.44%	23.65%	-68.81%	24.13%	22.35%
Pre Tax Income Margin	24.94%	27.61%	25.25%	21.87%	24.30%	24.61%	24.59%	24.60%	-104.78%	24.72%	23.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.87	8.00	6.84	5.45	5.41	5.20	5.00	4.88	-14.78	4.80	4.92
NOPAT to Interest Expense	5.57	6.11	5.21	4.61	3.96	3.99	3.81	3.73	-10.37	3.71	3.81
EBIT Less CapEx to Interest Expense	7.55	7.86	6.67	5.36	5.21	5.08	4.83	4.79	-14.92	4.70	4.78
NOPAT Less CapEx to Interest Expense	5.25	5.98	5.05	4.52	3.75	3.87	3.65	3.64	-10.50	3.61	3.67
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	24.00%	18.79%	18.35%	12.66%	11.94%	-30.99%	-30.58%	-44.21%	-60.75%	23.77%	23.97%

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

When does Prestige Consumer Healthcare's financial year end?

According to the most recent income statement we have on file, Prestige Consumer Healthcare's fiscal year ends in March. Their fiscal year 2025 ended on March 31, 2025.

How has Prestige Consumer Healthcare's net income changed over the last 10 years?

Prestige Consumer Healthcare's net income appears to be on an upward trend, with a most recent value of $214.61 million in 2025, rising from $78.26 million in 2015. The previous period was $209.34 million in 2024. See where experts think Prestige Consumer Healthcare is headed by visiting Prestige Consumer Healthcare's forecast page.

What is Prestige Consumer Healthcare's operating income?

Prestige Consumer Healthcare's total operating income in 2025 was $336.78 million, based on the following breakdown:

Total Gross Profit: $634.46 million
Total Operating Expenses: $297.69 million

How has Prestige Consumer Healthcare revenue changed over the last 10 years?

Over the last 10 years, Prestige Consumer Healthcare's total revenue changed from $714.62 million in 2015 to $1.14 billion in 2025, a change of 59.2%.

How much debt does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare's total liabilities were at $1.57 billion at the end of 2025, a 5.8% decrease from 2024, and a 22.2% decrease since 2015.

How much cash does Prestige Consumer Healthcare have?

In the past 10 years, Prestige Consumer Healthcare's cash and equivalents has ranged from $21.32 million in 2015 to $97.88 million in 2025, and is currently $97.88 million as of their latest financial filing in 2025.

How has Prestige Consumer Healthcare's book value per share changed over the last 10 years?

Over the last 10 years, Prestige Consumer Healthcare's book value per share changed from 12.01 in 2015 to 37.04 in 2025, a change of 208.5%.

Related Companies

This page (NYSE:PBH) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Financials

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Financials

Annual Income Statements for Prestige Consumer Healthcare

Quarterly Income Statements for Prestige Consumer Healthcare

Annual Cash Flow Statements for Prestige Consumer Healthcare

Quarterly Cash Flow Statements for Prestige Consumer Healthcare

Annual Balance Sheets for Prestige Consumer Healthcare

Quarterly Balance Sheets for Prestige Consumer Healthcare

Annual Metrics And Ratios for Prestige Consumer Healthcare

Quarterly Metrics And Ratios for Prestige Consumer Healthcare

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools